Tumor angiogenesis and novel antiangiogenic strategies

被引:111
作者
Gordon, Michael S. [1 ]
Mendelson, David S. [1 ]
Kato, Gerry [1 ]
机构
[1] Premiere Oncol Arizona, Scottsdale, AZ 85258 USA
关键词
angiogenesis; VEGFR; PDGFR; breast cancer; targeted agents; ENDOTHELIAL GROWTH-FACTOR; METASTATIC BREAST-CANCER; FACTOR EXPRESSION; CARCINOMA CELLS; IN-VIVO; C-KIT; MECHANISMS; INHIBITOR; THERAPY; PLUS;
D O I
10.1002/ijc.25026
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Angiogenesis is essential for the development and growth of tumors. It is a highly regulated process that requires cross-talk between signaling pathways at all stages of blood vessel development and tumor growth, from the recruitment of endothelial cells to vessel maturation. This review summarizes tumor angiogenesis and describes the key signaling pathways governing blood vessel development. The role of angiogenesis in various tumor types is discussed, but the focus is on invasive breast cancer, a disease that will affect 182,000 women in the USA in 2008. Research efforts over the past decade have identified numerous potential, as well as proven therapies with activity in breast cancer. These include chemotherapeutics as well as therapies that inhibit specific angiogenic pathways known as targeted agents. Some of the data from single- and multitargeted antiangiogenic agents are described in this review. "Published 2008 Wiley-Liss, Inc. This article is a US Government work, and, as such, is in the public domain in the United States of America."
引用
收藏
页码:1777 / 1787
页数:11
相关论文
共 62 条
[1]   Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells [J].
Aicher, A ;
Heeschen, C ;
Mildner-Rihm, C ;
Urbich, C ;
Ihling, C ;
Technau-Ihling, K ;
Zeiher, AM ;
Dimmeler, S .
NATURE MEDICINE, 2003, 9 (11) :1370-1376
[2]   VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells [J].
Asahara, T ;
Takahashi, T ;
Masuda, H ;
Kalka, C ;
Chen, DH ;
Iwaguro, H ;
Inai, Y ;
Silver, M ;
Isner, JM .
EMBO JOURNAL, 1999, 18 (14) :3964-3972
[3]  
BACHELOT T, 2009, CANCER RES, V69, pA4115
[4]   Endothelin receptors as novel targets in tumor therapy [J].
Bagnato A. ;
Natali P.G. .
Journal of Translational Medicine, 2 (1)
[5]   Mechanisms of Disease: angiogenesis and the management of breast cancer [J].
Banerjee, Susana ;
Dowsett, Mitch ;
Ashworth, Alan ;
Martin, Lesley-Ann .
NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (09) :536-550
[6]   Tumorigenesis and the angiogenic switch [J].
Bergers, G ;
Benjamin, LE .
NATURE REVIEWS CANCER, 2003, 3 (06) :401-410
[7]   Modes of resistance to anti-angiogenic therapy [J].
Bergers, Gabriele ;
Hanahan, Douglas .
NATURE REVIEWS CANCER, 2008, 8 (08) :592-603
[8]   Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice [J].
Brantley-Sieders, Dana M. ;
Fang, Wei Bin ;
Hwang, Yoonha ;
Hicks, Donna ;
Chen, Jin .
CANCER RESEARCH, 2006, 66 (21) :10315-10324
[9]   Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane [J].
Burstein, Harold J. ;
Elias, Anthony D. ;
Rugo, Hope S. ;
Cobleigh, Melody A. ;
Wolff, Antonio C. ;
Eisenberg, Peter D. ;
Lehman, Mary ;
Adams, Bonne J. ;
Bello, Carlo L. ;
DePrimo, Samuel E. ;
Baum, Charles M. ;
Miller, Kathy D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (11) :1810-1816
[10]  
Cao YH, 2005, CELL CYCLE, V4, P228